Business
Esperion Announces Pricing of $225 Million Public Offering
ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the pricing of its previously
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"ANN ARBOR, Mich., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock. Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock at a combined public offering price of $7.00 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The short-term warrants have an exercise price of $9.00 per share, are exercisable immediately, and will expire two years following the date of issuance. H.C. Wainwright & Co. is acting as sole book-running manager for the offering. In addition, Esperion has granted the underwriter a 30-day option to purchase up to an additional 4,821,428 shares of common stock and/or warrants to purchase up to an additional 4,821,428 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the securities being sold in the offering are being offered by Esperion. The offering is expected to close on or about December 7, 2021, subject to satisfaction of customary closing conditions. The gross proceeds from the offering to Esperion, before deducting underwriting discounts and commissions and other offering expenses, excluding any proceeds that may be received upon the exercise of the option to purchase additional securities and any exercise of the warrants to purchase common stock, are expected to be approximately $225.0 million. Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, and general corporate purposes. Esperion may call all or any portion of the short-term warrants for cancellation, subject to certain conditions included in the warrants, at a price of $0.001 per warrant share at any time after the date that is three months following the public announcement by the Company of the top-line results from the CLEAR Outcomes trial, provided that, among other things, the volume weighted average price of the Company’s common stock exceeds $18.00 for 20 consecutiv...